Other
Adenomyosis
28
Pipeline Programs↗
8
Active Trials↗
12
Companies Involved↗
Adenomyosis is an emerging landscape with 28 programs across 12 companies. The most active players are Ipsen, GSK, Danco. 8 therapies are approved with 4 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 34
Analysis
Trial Status
25
clinical trials
Completed7 · 28%
Unknown status7 · 28%
Not yet recruiting5 · 20%
Withdrawn3 · 12%
Active, not recruiting1 · 4%
Enrolling by invitation1 · 4%
Other1 · 4%
Clinical Trials
Trial Activity
25 trials
Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis
Active, not recruiting·CCentre for Endocrinology and Reproductive Medicine, Italy·Phase 4·NCT03421639·300 enrolled
Ttt of Adenomyosis
Not yet recruiting·—·Phase 1·NCT06719934·100 enrolled
Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis
Completed·—·Phase 2/3·NCT03520439·134 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)